RLYB News and Press, Rallybio Corporation From 04/06/23

-- Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT -- -- In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a Monoclonal Anti-HPA-1a Antibody, in the First Quarter of 2023 -- Rallybio Corpo...

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Mont...

2023-03-30 08:44:07 ET SCYNEXIS ( SCYX ) +93% jumps 92% on licensing deal with GSK for anti-fungal agent. Freight Technologies ( FRGT ) +23% warded Whirlpool Contract. Cazoo Group ( CZOO ) +19% FY earnings call release Altus Power ( AMPS ) +...

2023-03-15 07:29:49 ET Summary RLYB has a diverse pipeline targeting rare diseases. Recently, it announced proof of concept data. The company has a decent cash runway and looks interesting. Rallybio ( RLYB ) is a microcap, early stage developer of rare disease therap...

2023-03-06 09:28:52 ET Rallybio press release ( NASDAQ: RLYB ): Q4 GAAP EPS of -$0.46 beats by $0.14 . Cash and cash equivalents of $168.99M For further details see: Rallybio GAAP EPS of -$0.46 beats by $0.14

-- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Pr...

-- RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT -- -- C...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: ...

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development...

Rallybio ( NASDAQ: RLYB ) on Tuesday said it had appointed Jonathan Lieber as its CFO, effective Feb 1. Lieber succeeds RLYB co-founder Jeffrey Fryer, the company said in a statement . Fryer's departure was announced by the company in June last year. According to RLYB...